

# COVID-19 in patients with seizures: considerations for therapeutic management and potential drug-drug interactions

Shreshtha Jain<sup>1</sup>, Heidrun Potschka<sup>2</sup>, P Prarthana Chandra<sup>3</sup>, Manjari Tripathi<sup>4</sup>, and Divya Vohora<sup>1</sup>

<sup>1</sup>Jamia Hamdard

<sup>2</sup>Ludwig-Maximilians-Universitat Munchen

<sup>3</sup>Hamdard Institute of Medical Science and Research

<sup>4</sup>All India Institute of Medical Sciences

March 30, 2022

## Abstract

In regard to the global pandemic of COVID-19, it seems that persons with epilepsy (PWE) are not more vulnerable to get infected by SARS-CoV-2, nor are they more susceptible to a critical course of the disease. However, management of acute seizures in patients with COVID-19 as well as management of PWE and COVID-19 needs to consider potential drug-drug interactions between antiseizure drugs and candidate drugs currently assessed as therapeutic options for COVID-19. Repurposing of several licensed and investigational drugs is discussed for therapeutic management of COVID-19. While for none of these approaches, efficacy and tolerability has been confirmed yet in sufficiently powered and controlled clinical studies, testing is ongoing with multiple clinical trials worldwide. Here, we have summarized the possible mechanisms of action of drugs currently considered as potential therapeutic options for COVID-19 management along with possible and confirmed drug-drug interactions that should be considered for a combination of antiseizure drugs and COVID-19 candidate drugs.

## Hosted file

Manuscript.docx available at <https://authorea.com/users/468082/articles/561923-covid-19-in-patients-with-seizures-considerations-for-therapeutic-management-and-potential-drug-drug-interactions>